ACRUX LIMITED - Announcements

0.00%

1.8¢

Market Cap $7.366M

Healthcare Drug Manufacturers - Specialty & Generic

Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is... Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

ACR	Receipt of second advance for FY25 R&D Tax Incentive	PRICE SENSITIVE	03/07/25	118.74KB	Share
ACR	Dapsone 7.5%, Gel launched in the United States	PRICE SENSITIVE	09/05/25	145.84KB	Share
ACR	Acrux CEO and Managing Director appointment	PRICE SENSITIVE	07/05/25	148.5KB	Share
ACR	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	337.37KB	Share
ACR	Acrux receives $1.73m advance on FY25 R&D Tax Incentive	PRICE SENSITIVE	03/04/25	117.26KB	Share
ACR	Investor Presentation February 2025	PRICE SENSITIVE	25/02/25	1.89MB	Share
ACR	Appendix 4D and December 2024 Half Year Accounts	PRICE SENSITIVE	25/02/25	1MB	Share
ACR	Acrux CEO announces plan to retire	PRICE SENSITIVE	07/02/25	96.14KB	Share
ACR	Monthly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/25	372.45KB	Share
ACR	Launch of 90 gram pack size of Dapsone 5%, Gel in US	PRICE SENSITIVE	16/01/25	111.26KB	Share
ACR	Acrux raises $1.34 million from SPP	PRICE SENSITIVE	23/12/24	112.51KB	Share
ACR	Investor Deck update, SPP Closes 18 December 2024, 5pm	PRICE SENSITIVE	17/12/24	1.94MB	Share
ACR	Commercialisation of Nitroglycerin Ointment	PRICE SENSITIVE	13/12/24	153.62KB	Share
ACR	Share Purchase Plan Offer Booklet	PRICE SENSITIVE	06/12/24	350.91KB	Share
ACR	Investor Presentation	PRICE SENSITIVE	05/12/24	2.05MB	Share
ACR	Share Placement successfully concluded and SPP launched	PRICE SENSITIVE	05/12/24	168.21KB	Share
ACR	FDA Approval - Nitroglycerin Ointment	PRICE SENSITIVE	04/12/24	149.39KB	Share
ACR	Trading Halt	PRICE SENSITIVE	03/12/24	196.44KB	Share
ACR	AGM Presentation	PRICE SENSITIVE	21/11/24	2.84MB	Share
ACR	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	487.25KB	Share
ACR	FY24 R&D Tax Incentive rebate received	PRICE SENSITIVE	02/10/24	116.83KB	Share
ACR	ASX Small and Mid Cap Conference presentation	PRICE SENSITIVE	24/09/24	1.57MB	Share
ACR	FY24 Full Year Results - Investor Presentation	PRICE SENSITIVE	29/08/24	1.02MB	Share
ACR	Appendix 4E and FY24 Full Year Statutory Accounts	PRICE SENSITIVE	29/08/24	13.45MB	Share
ACR	FDA Approval received for Dapsone Gel, 7.5%	PRICE SENSITIVE	27/08/24	149.88KB	Share
ACR	Quarterly Activities Report and Appendix 4C - June 2024	PRICE SENSITIVE	26/07/24	481.67KB	Share
ACR	Acrux presentation to Bioshares, 18th Biotech Summit	PRICE SENSITIVE	15/07/24	1.44MB	Share
ACR	RDTI funding facility secured	PRICE SENSITIVE	28/06/24	117.41KB	Share
ACR	Acrux presentation at Hidden Gems in Lifesciences Forum	PRICE SENSITIVE	13/06/24	1.11MB	Share
ACR	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	417.11KB	Share
ACR	Launch of Dapsone 5%, Gel in the United States	PRICE SENSITIVE	03/04/24	73.21KB	Share
ACR	Investor Presentation Half Year Accounts	PRICE SENSITIVE	27/02/24	699.42KB	Share
ACR	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	27/02/24	687.06KB	Share
ACR	Appendix 4C and Activities Statement	PRICE SENSITIVE	31/01/24	223.05KB	Share
ACR	Address of Chair and CEO to AGM	PRICE SENSITIVE	29/11/23	890.47KB	Share
ACR	Acrux receives $2.88m R&D Tax Incentive Rebate for FY23	PRICE SENSITIVE	08/11/23	114.91KB	Share
ACR	Appendix 4C and Activities Statement	PRICE SENSITIVE	27/10/23	212.15KB	Share
ACR	Investor Presentation - Acrux FY23 Results	PRICE SENSITIVE	25/08/23	620.84KB	Share
ACR	Appendix 4E and FY23 Annual Report	PRICE SENSITIVE	25/08/23	10.71MB	Share
ACR	Activities Statement and Appendix 4C	PRICE SENSITIVE	27/07/23	219.09KB	Share
ACR	Acrux's seventh generic dossier accepted by FDA for review	PRICE SENSITIVE	04/07/23	136.02KB	Share
ACR	4th FDA ANDA approval received - Dapsone Gel, 5%	PRICE SENSITIVE	07/06/23	149.43KB	Share
ACR	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/04/23	208.11KB	Share
ACR	Appendix 4D and Half Year Report	PRICE SENSITIVE	23/02/23	642.71KB	Share
ACR	Quarterly Activities / Appendix 4C Cashflow Report	PRICE SENSITIVE	30/01/23	324.06KB	Share
ACR	Gedeon Richter buyout Lenzetto Royalties for EUR4.1million	PRICE SENSITIVE	23/01/23	76.86KB	Share
ACR	Launch of prilocaine and lidocaine cream in United States	PRICE SENSITIVE	21/12/22	169.98KB	Share
ACR	Mutual Termination of Co-Development Agreement	PRICE SENSITIVE	15/12/22	40.8KB	Share
ACR	Chairman and CEO address to AGM	PRICE SENSITIVE	23/11/22	889.08KB	Share
ACR	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/22	246.12KB	Share
ACR	Remaining balance of R&D Tax Incentive Rebate received	PRICE SENSITIVE	03/10/22	115.41KB	Share
ACR	Appendix 4E and FY22 Annual Report	PRICE SENSITIVE	26/08/22	7.47MB	Share
ACR	Acrux's sixth generic dossier accepted by FDA for review	PRICE SENSITIVE	08/08/22	153.25KB	Share
ACR	Acrux announces commercial agreement with Padagis	PRICE SENSITIVE	20/06/22	149.19KB	Share
ACR	Successful patent litigation outcome	PRICE SENSITIVE	30/05/22	172.29KB	Share
ACR	Appendix 4D, Half Year Accounts as at 31 December 2021	PRICE SENSITIVE	24/02/22	618.71KB	Share
ACR	Acrux and Harris terminate license agreement	PRICE SENSITIVE	11/10/21	128.38KB	Share
ACR	Acrux's fifth generic dossier accepted by FDA for review	PRICE SENSITIVE	13/09/21	193.42KB	Share
ACR	Acrux Investor Presentation - September 2021	PRICE SENSITIVE	02/09/21	947.81KB	Share
ACR	US Launch - Testosterone Topical Solution	PRICE SENSITIVE	26/08/21	201.45KB	Share
ACR	Appendix 4E and Financial Report	PRICE SENSITIVE	25/08/21	1.15MB	Share
ACR	Acrux receives third FDA ANDA approval	PRICE SENSITIVE	28/07/21	165.58KB	Share
ACR	Acrux Receives FDA Approval - Generic Efinaconazole Solution	PRICE SENSITIVE	22/06/21	193.2KB	Share
ACR	Acrux confirms patent challenge	PRICE SENSITIVE	08/06/21	221.62KB	Share
ACR	Acrux's fourth generic dossier accepted by FDA for review	PRICE SENSITIVE	15/04/21	241.93KB	Share
ACR	Acrux Investor Presentation	PRICE SENSITIVE	25/02/21	1.04MB	Share
ACR	Appendix 4D and Half Year Accounts - for the 31 Dec ac	PRICE SENSITIVE	25/02/21	1.66MB	Share
ACR	Share Purchase Plan Closes Oversubscribed	PRICE SENSITIVE	02/02/21	179.96KB	Share
ACR	Acrux Receives FDA Approval - Generic Testosterone Solution	PRICE SENSITIVE	12/01/21	155.5KB	Share
ACR	Acrux Ltd Share Purchase Plan Offer Booklet	PRICE SENSITIVE	08/01/21	823.79KB	Share
ACR	Acrux Raises $7.8m Via Placement and Announces SPP	PRICE SENSITIVE	21/12/20	203.34KB	Share
ACR	Trading Halt	PRICE SENSITIVE	17/12/20	183.82KB	Share
ACR	Acrux Signs Licensing Agreement with Dash Pharmaceuticals	PRICE SENSITIVE	12/10/20	153.97KB	Share
ACR	Acrux Investor Presentation	PRICE SENSITIVE	25/08/20	1.15MB	Share
ACR	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	24/08/20	1.67MB	Share
ACR	Acrux Signs Licensing Agreement with Harris Pharmaceutical	PRICE SENSITIVE	11/08/20	195.67KB	Share
ACR	Acrux Signs Co-Development Agreement With Amring	PRICE SENSITIVE	18/06/20	177.29KB	Share
ACR	Acrux Signs Licensing Agreement With TruPharma	PRICE SENSITIVE	29/05/20	169.6KB	Share
ACR	Trading Halt	PRICE SENSITIVE	27/05/20	200.12KB	Share
ACR	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	25/02/20	982.5KB	Share
ACR	Receipt of first R&D Tax Incentive Rebate	PRICE SENSITIVE	24/10/19	135.27KB	Share
ACR	Acrux Ltd Investor Presentation and Full Year Results	PRICE SENSITIVE	26/08/19	713.5KB	Share
ACR	Appendix 4E & Full Year Statutory Accounts	PRICE SENSITIVE	23/08/19	2.44MB	Share
ACR	Jublia Patent Litigation Settlement	PRICE SENSITIVE	03/04/19	123.89KB	Share
ACR	Investor Presentation	PRICE SENSITIVE	25/02/19	837.85KB	Share
ACR	Appendix 4D and Half-Year Financial Report to 31 Dec 2018	PRICE SENSITIVE	21/02/19	965.44KB	Share
ACR	Acrux Receives $2.057m R&D Tax Incentive Rebate	PRICE SENSITIVE	21/01/19	106.75KB	Share
ACR	Acrux has second generic dossier accepted for review by FDA	PRICE SENSITIVE	17/10/18	215.94KB	Share
ACR	Acrux confirms patent challenge for generic of efinaconazole	PRICE SENSITIVE	24/09/18	157.3KB	Share
ACR	Appendix 4E and 2018 Financial Report	PRICE SENSITIVE	16/08/18	1.44MB	Share
ACR	Acrux Submits First-To-File Generic of Jublia	PRICE SENSITIVE	02/08/18	202KB	Share
ACR	Appendix 4D and Half-Year Report to 31 December 2017	PRICE SENSITIVE	20/02/18	1.23MB	Share
ACR	Axiron Net Sales Quarter to December 2017	PRICE SENSITIVE	01/02/18	331.65KB	Share
ACR	Axiron Patents Appeal Decision	PRICE SENSITIVE	23/11/17	331.46KB	Share
ACR	Axiron Net Sales Quarter to September 2017	PRICE SENSITIVE	25/10/17	331.93KB	Share
ACR	Axiron License Agreement Terminated	PRICE SENSITIVE	06/09/17	335.33KB	Share
ACR	Appendix 4E and 2017 Financial Report	PRICE SENSITIVE	22/08/17	1.93MB	Share
ACR	Teva Launches Generic Version of Axiron in United States	PRICE SENSITIVE	21/08/17	328.43KB	Share
ACR	Axiron Net Sales Quarter to 30 June 2017	PRICE SENSITIVE	26/07/17	338.45KB	Share
ACR	Axiron Generic Launched In The United States	PRICE SENSITIVE	06/07/17	332.87KB	Share

ACR Receipt of second advance for FY25 R&D Tax Incentive
03/07/25	PRICE SENSITIVE	118.74KB	Share
ACR Dapsone 7.5%, Gel launched in the United States
09/05/25	PRICE SENSITIVE	145.84KB	Share
ACR Acrux CEO and Managing Director appointment
07/05/25	PRICE SENSITIVE	148.5KB	Share
ACR Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	337.37KB	Share
ACR Acrux receives $1.73m advance on FY25 R&D Tax Incentive
03/04/25	PRICE SENSITIVE	117.26KB	Share
ACR Investor Presentation February 2025
25/02/25	PRICE SENSITIVE	1.89MB	Share
ACR Appendix 4D and December 2024 Half Year Accounts
25/02/25	PRICE SENSITIVE	1MB	Share
ACR Acrux CEO announces plan to retire
07/02/25	PRICE SENSITIVE	96.14KB	Share
ACR Monthly Activities/Appendix 4C Cash Flow Report
30/01/25	PRICE SENSITIVE	372.45KB	Share
ACR Launch of 90 gram pack size of Dapsone 5%, Gel in US
16/01/25	PRICE SENSITIVE	111.26KB	Share
ACR Acrux raises $1.34 million from SPP
23/12/24	PRICE SENSITIVE	112.51KB	Share
ACR Investor Deck update, SPP Closes 18 December 2024, 5pm
17/12/24	PRICE SENSITIVE	1.94MB	Share
ACR Commercialisation of Nitroglycerin Ointment
13/12/24	PRICE SENSITIVE	153.62KB	Share
ACR Share Purchase Plan Offer Booklet
06/12/24	PRICE SENSITIVE	350.91KB	Share
ACR Investor Presentation
05/12/24	PRICE SENSITIVE	2.05MB	Share
ACR Share Placement successfully concluded and SPP launched
05/12/24	PRICE SENSITIVE	168.21KB	Share
ACR FDA Approval - Nitroglycerin Ointment
04/12/24	PRICE SENSITIVE	149.39KB	Share
ACR Trading Halt
03/12/24	PRICE SENSITIVE	196.44KB	Share
ACR AGM Presentation
21/11/24	PRICE SENSITIVE	2.84MB	Share
ACR Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	487.25KB	Share
ACR FY24 R&D Tax Incentive rebate received
02/10/24	PRICE SENSITIVE	116.83KB	Share
ACR ASX Small and Mid Cap Conference presentation
24/09/24	PRICE SENSITIVE	1.57MB	Share
ACR FY24 Full Year Results - Investor Presentation
29/08/24	PRICE SENSITIVE	1.02MB	Share
ACR Appendix 4E and FY24 Full Year Statutory Accounts
29/08/24	PRICE SENSITIVE	13.45MB	Share
ACR FDA Approval received for Dapsone Gel, 7.5%
27/08/24	PRICE SENSITIVE	149.88KB	Share
ACR Quarterly Activities Report and Appendix 4C - June 2024
26/07/24	PRICE SENSITIVE	481.67KB	Share
ACR Acrux presentation to Bioshares, 18th Biotech Summit
15/07/24	PRICE SENSITIVE	1.44MB	Share
ACR RDTI funding facility secured
28/06/24	PRICE SENSITIVE	117.41KB	Share
ACR Acrux presentation at Hidden Gems in Lifesciences Forum
13/06/24	PRICE SENSITIVE	1.11MB	Share
ACR Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	417.11KB	Share
ACR Launch of Dapsone 5%, Gel in the United States
03/04/24	PRICE SENSITIVE	73.21KB	Share
ACR Investor Presentation Half Year Accounts
27/02/24	PRICE SENSITIVE	699.42KB	Share
ACR Appendix 4D and Half Year Accounts
27/02/24	PRICE SENSITIVE	687.06KB	Share
ACR Appendix 4C and Activities Statement
31/01/24	PRICE SENSITIVE	223.05KB	Share
ACR Address of Chair and CEO to AGM
29/11/23	PRICE SENSITIVE	890.47KB	Share
ACR Acrux receives $2.88m R&D Tax Incentive Rebate for FY23
08/11/23	PRICE SENSITIVE	114.91KB	Share
ACR Appendix 4C and Activities Statement
27/10/23	PRICE SENSITIVE	212.15KB	Share
ACR Investor Presentation - Acrux FY23 Results
25/08/23	PRICE SENSITIVE	620.84KB	Share
ACR Appendix 4E and FY23 Annual Report
25/08/23	PRICE SENSITIVE	10.71MB	Share
ACR Activities Statement and Appendix 4C
27/07/23	PRICE SENSITIVE	219.09KB	Share
ACR Acrux's seventh generic dossier accepted by FDA for review
04/07/23	PRICE SENSITIVE	136.02KB	Share
ACR 4th FDA ANDA approval received - Dapsone Gel, 5%
07/06/23	PRICE SENSITIVE	149.43KB	Share
ACR Quarterly Activities/Appendix 4C Cash Flow Report
26/04/23	PRICE SENSITIVE	208.11KB	Share
ACR Appendix 4D and Half Year Report
23/02/23	PRICE SENSITIVE	642.71KB	Share
ACR Quarterly Activities / Appendix 4C Cashflow Report
30/01/23	PRICE SENSITIVE	324.06KB	Share
ACR Gedeon Richter buyout Lenzetto Royalties for EUR4.1million
23/01/23	PRICE SENSITIVE	76.86KB	Share
ACR Launch of prilocaine and lidocaine cream in United States
21/12/22	PRICE SENSITIVE	169.98KB	Share
ACR Mutual Termination of Co-Development Agreement
15/12/22	PRICE SENSITIVE	40.8KB	Share
ACR Chairman and CEO address to AGM
23/11/22	PRICE SENSITIVE	889.08KB	Share
ACR Quarterly Activities/Appendix 4C Cash Flow Report
28/10/22	PRICE SENSITIVE	246.12KB	Share
ACR Remaining balance of R&D Tax Incentive Rebate received
03/10/22	PRICE SENSITIVE	115.41KB	Share
ACR Appendix 4E and FY22 Annual Report
26/08/22	PRICE SENSITIVE	7.47MB	Share
ACR Acrux's sixth generic dossier accepted by FDA for review
08/08/22	PRICE SENSITIVE	153.25KB	Share
ACR Acrux announces commercial agreement with Padagis
20/06/22	PRICE SENSITIVE	149.19KB	Share
ACR Successful patent litigation outcome
30/05/22	PRICE SENSITIVE	172.29KB	Share
ACR Appendix 4D, Half Year Accounts as at 31 December 2021
24/02/22	PRICE SENSITIVE	618.71KB	Share
ACR Acrux and Harris terminate license agreement
11/10/21	PRICE SENSITIVE	128.38KB	Share
ACR Acrux's fifth generic dossier accepted by FDA for review
13/09/21	PRICE SENSITIVE	193.42KB	Share
ACR Acrux Investor Presentation - September 2021
02/09/21	PRICE SENSITIVE	947.81KB	Share
ACR US Launch - Testosterone Topical Solution
26/08/21	PRICE SENSITIVE	201.45KB	Share
ACR Appendix 4E and Financial Report
25/08/21	PRICE SENSITIVE	1.15MB	Share
ACR Acrux receives third FDA ANDA approval
28/07/21	PRICE SENSITIVE	165.58KB	Share
ACR Acrux Receives FDA Approval - Generic Efinaconazole Solution
22/06/21	PRICE SENSITIVE	193.2KB	Share
ACR Acrux confirms patent challenge
08/06/21	PRICE SENSITIVE	221.62KB	Share
ACR Acrux's fourth generic dossier accepted by FDA for review
15/04/21	PRICE SENSITIVE	241.93KB	Share
ACR Acrux Investor Presentation
25/02/21	PRICE SENSITIVE	1.04MB	Share
ACR Appendix 4D and Half Year Accounts - for the 31 Dec ac
25/02/21	PRICE SENSITIVE	1.66MB	Share
ACR Share Purchase Plan Closes Oversubscribed
02/02/21	PRICE SENSITIVE	179.96KB	Share
ACR Acrux Receives FDA Approval - Generic Testosterone Solution
12/01/21	PRICE SENSITIVE	155.5KB	Share
ACR Acrux Ltd Share Purchase Plan Offer Booklet
08/01/21	PRICE SENSITIVE	823.79KB	Share
ACR Acrux Raises $7.8m Via Placement and Announces SPP
21/12/20	PRICE SENSITIVE	203.34KB	Share
ACR Trading Halt
17/12/20	PRICE SENSITIVE	183.82KB	Share
ACR Acrux Signs Licensing Agreement with Dash Pharmaceuticals
12/10/20	PRICE SENSITIVE	153.97KB	Share
ACR Acrux Investor Presentation
25/08/20	PRICE SENSITIVE	1.15MB	Share
ACR Appendix 4E and Full Year Statutory Accounts
24/08/20	PRICE SENSITIVE	1.67MB	Share
ACR Acrux Signs Licensing Agreement with Harris Pharmaceutical
11/08/20	PRICE SENSITIVE	195.67KB	Share
ACR Acrux Signs Co-Development Agreement With Amring
18/06/20	PRICE SENSITIVE	177.29KB	Share
ACR Acrux Signs Licensing Agreement With TruPharma
29/05/20	PRICE SENSITIVE	169.6KB	Share
ACR Trading Halt
27/05/20	PRICE SENSITIVE	200.12KB	Share
ACR Appendix 4D and Half Year Financial Report
25/02/20	PRICE SENSITIVE	982.5KB	Share
ACR Receipt of first R&D Tax Incentive Rebate
24/10/19	PRICE SENSITIVE	135.27KB	Share
ACR Acrux Ltd Investor Presentation and Full Year Results
26/08/19	PRICE SENSITIVE	713.5KB	Share
ACR Appendix 4E & Full Year Statutory Accounts
23/08/19	PRICE SENSITIVE	2.44MB	Share
ACR Jublia Patent Litigation Settlement
03/04/19	PRICE SENSITIVE	123.89KB	Share
ACR Investor Presentation
25/02/19	PRICE SENSITIVE	837.85KB	Share
ACR Appendix 4D and Half-Year Financial Report to 31 Dec 2018
21/02/19	PRICE SENSITIVE	965.44KB	Share
ACR Acrux Receives $2.057m R&D Tax Incentive Rebate
21/01/19	PRICE SENSITIVE	106.75KB	Share
ACR Acrux has second generic dossier accepted for review by FDA
17/10/18	PRICE SENSITIVE	215.94KB	Share
ACR Acrux confirms patent challenge for generic of efinaconazole
24/09/18	PRICE SENSITIVE	157.3KB	Share
ACR Appendix 4E and 2018 Financial Report
16/08/18	PRICE SENSITIVE	1.44MB	Share
ACR Acrux Submits First-To-File Generic of Jublia
02/08/18	PRICE SENSITIVE	202KB	Share
ACR Appendix 4D and Half-Year Report to 31 December 2017
20/02/18	PRICE SENSITIVE	1.23MB	Share
ACR Axiron Net Sales Quarter to December 2017
01/02/18	PRICE SENSITIVE	331.65KB	Share
ACR Axiron Patents Appeal Decision
23/11/17	PRICE SENSITIVE	331.46KB	Share
ACR Axiron Net Sales Quarter to September 2017
25/10/17	PRICE SENSITIVE	331.93KB	Share
ACR Axiron License Agreement Terminated
06/09/17	PRICE SENSITIVE	335.33KB	Share
ACR Appendix 4E and 2017 Financial Report
22/08/17	PRICE SENSITIVE	1.93MB	Share
ACR Teva Launches Generic Version of Axiron in United States
21/08/17	PRICE SENSITIVE	328.43KB	Share
ACR Axiron Net Sales Quarter to 30 June 2017
26/07/17	PRICE SENSITIVE	338.45KB	Share
ACR Axiron Generic Launched In The United States
06/07/17	PRICE SENSITIVE	332.87KB	Share

REFRESH

1 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.8¢		Change 0.000(0.00%)		Mkt cap ! $7.366M

Open	High	Low	Value	Volume
1.8¢	1.8¢	1.8¢	$5.04K	280K

Buyers (Bids)

No.	Vol.	Price($)
6	916823	1.7¢

Sellers (Offers)

Price($)	Vol.	No.
1.9¢	265520	1

View Market Depth

No.	Vol.	Price($)
6	916823	0.017
11	1275173	0.016
5	1311882	0.015
2	140000	0.014
3	486850	0.013

Price($)	Vol.	No.
0.019	265520	1
0.020	56617	4
0.021	111922	1
0.022	100000	1
0.023	381179	1

Last trade - 14.14pm 29/07/2025 (20 minute delay)


Last 1.8¢		Change 0.000 ( 5.26 %)
Open	High	Low	Volume
1.8¢	1.8¢	1.8¢	53130
Last updated 11.05am 29/07/2025 ?

ACR (ASX) Chart

ACRUX LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available